CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 283 enrolled
Drug / intervention
Zofenopril 30 mg +2 moredrug
Likely dose
Zofenopril 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05257148
NCT05257148Phase 4Completed
CompareCT.gov

Open-label, Multicenter, Multinational, Interventional Clinical Trial to Assess Effectiveness and SAfety of the Extemporaneous Combination of Nebivolol and Zofenopril Calcium in Grade 1 to 2 Hypertensive patIents Versus Each mOnotherapy

Menarini International Operations Luxembourg SA·interventional·Posted Feb 25, 2022·Updated Sep 20, 2024

In Brief

A Phase 4 clinical trial evaluating Zofenopril 30 mg, Nebivolol 5 mg, and 1 other intervention for Hypertension. Completed, enrolled 283 participants across 1 site.

Detailed Summary

Open-label, interventional clinical trial to assess effectiveness and safety of the extemporaneous combination of nebivolol and zofenopril calcium in grade 1 to 2 hypertensive patients versus each monotherapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedFeb 25, 2022
Enrollment StartMay 26, 2021
Primary CompletionDec 22, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.4 years ago

Interventions

Zofenopril 30 mgdrug

Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake

Nebivolol 5 mgdrug

Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake

Zofenopril 30 mg + Nebivolol 5 mgdrug

Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake